TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Locked Versus Unlocked Set Screws in Intramedullary Fixation of Intertrochanteric Fractures

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~All subjects 18 years or older who are:~* mentally competent to give consent and complete the follow up questionnaires~* being treated for an intertrochanteric hip fracture,~* classified as Arbeitsgemeinschaft für Osteosynthesefragen/Orthopaedic Trauma Association (AO/OTA) 31-A2 or A3~* plan to be treated with an intramedullary hip screw~Exclusion Criteria:~* infection in the involved joint or surrounding soft tissues,~* pathological fractures as a result of metastatic or primary bone tumors, progressive or debilitating neurological conditions resulting in significant movement or gait disorders, congenital bone disorders or heritable bone disorders (excluding osteoporosis and osteopenia),~* severe dementia,~* nonambulatory patients.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Locked Set Screw (Type: ACTIVE_COMPARATOR): In this arm, subjects who have sustained an intertrochanteric hip fracture (OTA classification A2 and A3) will undergo fixation with an intramedullary hip screw with locking of the set screw.
- Unlocked Set Screw (Type: ACTIVE_COMPARATOR): In this arm, subjects who have sustained an intertrochanteric hip fracture (OTA classification A2 and A3) will undergo fixation with an intramedullary hip screw without locking of the set screw.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Open-label Treatment Extension Study for Patients Who Complete Study RNA200103-201

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients who completed 48 weeks of treatment in study RNA200103-201~Exclusion Criteria:~* Patients who were determined to be treatment failures in study RNA200103-201~* Patients who experienced a serious adverse event judged to be related to study drug in study RNA200103-201~* Patients with a serum creatinine greater than 2.0 mg/dl on two consecutive determinations in study RNA200103-201

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety and Efficacy of Basmisanil in Adults With Severe Motor Impairment Following an Ischemic Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Radiologic assessment confirming an acute middle cerebral artery ischemic stroke~* Index stroke occurred within the past 3-4 days~* Inpatient males and females~* Severe hemiparesis or hemiplegia defined by FMMS score less than or equal to (\</=) 35~* Sufficient speech, vision and hearing to participate in study evaluations~Exclusion Criteria:~* NIHSS greater than (\>) 20~* Severe aphasia that prevents a participant from following directions in rehabilitation~* Significant deficit from prior strokes or pre-existing motor deficit~* History of epilepsy, neurosurgery, severe head trauma or central nervous system infections that have residual symptomatology or have required treatment in the last 12 months~* Known or suspected clinical seizure post-index stroke~* History of pre-existing dementia or use of medications for dementia~* History of clinically significant pre-existing psychiatric conditions within 12 months prior to stroke~* Due to undergo carotid surgery within the next 4 months~* Enrollment/participation in any interventional study (clinical trial) involving an investigational drug (unapproved) or non-drug treatment within the prior 3 months or 6 times the half-life (whichever is longer)~* Clinically relevant medical conditions that would likely interfere with the study conduct and scheduled assessments~* Contraindication to magnetic resonance imaging (MRI) or conditions which render interpretation of MRI difficult

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Basmisanil (Type: EXPERIMENTAL): Basmisanil at a dose of 240 milligrams (mg) orally twice daily for 90 days.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo matched to basmisanil orally twice daily for 90 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Thermogard™ Efficacy Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult males and non-pregnant females ages 18-70 with greater than 20% TBSA burns requiring excision and grafting and in need of a central venous catheter per ICU admission criteria.~* Patient or patient's surrogate must be able to verbalize understanding and willingness to participate in the study and provide written informed consent~Exclusion Criteria:~* Pregnancy. All females admitted to the burn ICU undergo routine serum hCG to determine pregnancy status. Those found to be pregnant will be excluded from entry into the study~* Burn patients enrolled in recombinant Factor VII study due to the theoretical increased risk for clot formation~* Basic and advanced enlisted trainees~* Age greater than 70 years old due to increased mortality rate among those severely burned~* Conditions which make placement of a central venous catheters a greater than normal risk (vascular anomalies, previous vascular surgery, etc.)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- A (Type: EXPERIMENTAL): Burn patients with \>20% TBSA burns scheduled to undergo debridement and grafting who will have placed the Thermogard™ central venous warming catheter by Alsius
- B (Type: ACTIVE_COMPARATOR): Burn patients with \>20% TBSA burns scheduled to undergo debridement and grafting who will have placed a central venous catheter as a part of their routine burn management

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Telephone Support to Improve Adherence to Anti-HIV Medications

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Enrollment in an AIDS Clinical Trials Group (ACTG) treatment study that is an approved A5251 parent or coenrolling partner study (ACTG parent study participant) or not enrolled in one of the ACTG parent studies, but receiving routine HIV patient care at an institution that was also an ACTG-funded site (ACTG clinic patient participant).~* Virologic failure on combination antiretroviral therapy (ART), with an HIV-1 genotype conducted on or soon after the failure, within 16 weeks prior to entry. Availability of HIV-1 genotype results at entry.~* History of prior nonadherence to ART during the past year documented either by patient self-report or recorded in the patient's medical record~* Most recent HIV-1 RNA value of at least 200 copies/mL, obtained within 90 days prior to study entry and measured using any FDA-approved test for quantifying HIV-1 RNA~* Initiating or restarting an ART regimen with 2 or more active ARV medications within 3 days after randomization. The regimen must have been selected for the participant prior to the time of randomization for A5251. An active ARV medication was defined as a medication to which the participant was expected to be susceptible based on HIV-1 resistance testing, as specified in the ACTG parent study, or determined by the participant's health care provider per standard of care.~Exclusion Criteria:~* No regular access to a phone. Candidates without phones may have elected to participate by calling the HIV nurse specialists using an 800 number, rather than being called by the HIV nurse specialist.~* Coenrollment in another adherence trial, unless approved by the A5251 study chair~* Current incarceration~* Any condition that, in the opinion of the site investigator, would have compromised the candidate's ability to participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Enhanced nursing telephone support with standard care (Type: EXPERIMENTAL): Participants received enhanced nursing telephone support plus care as usual.
- Standard care (Type: ACTIVE_COMPARATOR): Participants received care as usual.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Procedures for Sample Acquisition and Distribution for The Human Brain Collection Core

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: CROSS_SECTIONAL
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
* INCLUSION CRITERIA:~Brain tissue is needed from individuals suffering from a variety of neuropsychiatric disorders, including schizophrenia, anxiety disorders, suicide, bipolar disorder, depression, and substance use disorders (cocaine, alcohol, heroin or the like). In addition, brains from individuals without a history of neuropsychiatric disease will be needed as controls.~EXCLUSION CRITERIA:~An assessment is carried out on the information available from the referral source (generally a Medical Examiner s Office) prior to obtaining consent. This information is usually very succinct, indicating how the decedent was found and, if known, whether they had some psychiatric or obvious medical history. The following cases will be~excluded from collection:~* Severe mental retardation.~* Well documented, long lasting seizure disorder.~* Infections known to affect the brain such as syphilis, tuberculosis, with the exception of HIV infection.~* The body is decomposed. We consider collecting the brain up to three days after death.~* There is obvious damage to the brain by closed head injury or other trauma (gunshot wound, fall, etc.).~* There are brain infarcts, hemorrhages, tumors, stroke, or other brain lesions that destroy the normal brain structure.~* The patient has been maintained on a respirator (ventilator) for more than 12 hours in the period immediately prior to death.~* Major sepsis.~* Serious renal or hepatic disease.~* Multiple sclerosis (MS), Alzheimer s disease and other dementias and degenerative diseases.~* Known infection with Hepatitis C

- Gender: ALL
- Minimum Age: None
- Maximum Age: 120 Years
- Healthy Volunteers: f

Study Arms:
- psychiatric disorders (Type: None): decedents with and without psychiatric use disorders
- substance disorders (Type: None): decedents with and without substance use disorders

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Catheter Ablation of Atrial Fibrillation Using Hansen Medical Robotic Navigation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients with symptomatic AF planned for catheter ablation.~Exclusion Criteria:~* Age \< 18 years~* Previous ablation procedure~* Expected life expectancy \< 6 months~* Inability or unwillingness to sign consent~* Pregnancy~* Contraindications for the ablation procedure o Thrombus in the left atrium that fails to resolve with optimal oral anticoagulation therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- manual ablation (Type: OTHER): None
- robotic ablation (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy, Safety and Tolerability Study of Subcutaneous C.E.R.A. in Pre-Dialysis Participants With Chronic Renal Anemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Chronic renal anemia~* Hemoglobin concentration between 10.5 gram per deciliter (g/dL) and 12.5 g/dL~* Adequate iron status (serum ferritin greater than \[\>\] 100 nanogram per milliliter and Transferrin Saturation \>20 percent \[%\] or hypochromic red cells less than \[\<\] 10%)~* Continuous subcutaneous maintenance darbepoetin alfa therapy with same dosing interval during previous 2 months~Exclusion Criteria:~* Transfusion of red blood cells during previous 2 months~* Poorly controlled hypertension requiring hospitalization or interruption of darbepoetin alfa treatment in previous 6 months~* Acute or chronic bleeding~* Active malignant disease (except non-melanoma skin cancer)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- C.E.R.A. (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Buprenorphine as a Treatment in Opiate Dependent Pain Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of chronic refractory pain~* Clinical diagnosis of opiate dependency~Exclusion Criteria:~* unable to pay for medication~* enrolled in a methadone maintenance program~* homelessness~* major mental illness~* pregnant women~* prisoners~* terminal cancer pain

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tapering doses of buprenorphine (Type: ACTIVE_COMPARATOR): Participants assigned to this arm will receive tapering doses of buprenorphine for detoxification.
- Steady doses of buprenrophine (Type: EXPERIMENTAL): Participants assigned to this arm will receive a steady dose of buprenorphine for maintenance.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Vascular Boot Warming Program After Acute Deep Vein Thrombosis (DVT) ± Pulmonary Embolism (PE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Able to tolerate wearing a vascular boot, if randomized to this group.~* Diagnosis of acute DVT±PE (within 24 - 48 hours) and received approximately 24 hours of anticoagulation prior to starting the study.~Exclusion Criteria:~* Unable to tolerate wearing a vascular boot~* Unable to comply with keeping log of activity/ of wearing a vascular boot.~* Weight \> 300 pounds. (weight limit for the venous plethysmography chair)~* Previous history of DVT or PE.~* On anticoagulation for another purpose (example stroke prevention with atrial fibrillation).~* Patients who do not accept to participate in research studies.~* Pregnant women will not be allowed to participate~* Patients less than 18 yrs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of Care (Type: OTHER): Ultrasound of the leg with DVT and leg circumference measurement at 3 days, 10 days, and 3 months. Ultrasound data will include data on thrombus resolution, such as size and recanalization present.
- Vascular Boot Group (Type: OTHER): For each vascular boot session, the following data will be recorded:~Wearing the vascular boot during first 10 days of study for minimum of 30 minutes per day

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility of Text4US Program

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Parents/guardians (above the age of 18) of children (5-18 years old) who have completed potty training with pLUTS.~* Parents/patients that have never completed a bladder/food diary before~* Fluent in English~* Able to receive text messages on a mobile device~* Referred with a diagnosis of LUTS in our outpatient clinic~Exclusion Criteria:~1. Parents/guardians of children with~   1. neurogenic bladder~  2. Genitourinary (GU) abnormalities~  3. Detrusor sphincter dyssynergia (DSD)~  4. renal transplant patients (pre and post)~  5. abdominal or spinal surgeries within one year~  6. other chronic illness that is known to affect LUTS~  7. currently on immunosuppression of any kind~  8. younger than 5 years old or older than 18 years old~2. Younger than 18 years old~3. Not fluent in English~4. Not able to receive text messages~5. filled out a bladder and/or food diary before

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group 1: Diaries - SMS (Type: EXPERIMENTAL): Group 1 will be asked to complete a 2-day bladder diary + food diary during the first two weeks of the study, then will receive SMS Text reminders during the last 2 weeks of the study.~Both groups will complete a pre-survey at the beginning of the study and a post-survey after each phase of the study (total 2 post-surveys).
- Group 2: SMS - Diaries (Type: EXPERIMENTAL): Group 2 will receive SMS Text reminders during the first 2 weeks of the study, and then will be asked to complete a 2-day bladder diary + food diary during the last two weeks of the study.~Both groups will complete a pre-survey at the beginning of the study and a post-survey after each phase of the study (total 2 post-surveys).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Natrecor (Nesiritide) in Transplant-Eligible Management of Congestive Heart Failure-TMAC

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Meet the criteria for a United Network for Organ Sharing (UNOS) Status 1B heart transplant candidate, or, if outside the US, have comparable status~* must also be a primary transplant candidate waiting to receive a single cardiac allograft~* must be receiving continuous intravenous infusion of dobutamine or milrinone through a double-lumen central catheter or a double-lumen percutaneously inserted central catheter for at least 3 consecutive days before randomization~* must be willing and able to participate in the study assessments and follow up procedures~* male and female subjects of childbearing potential agree to use two highly effective methods of birth control for the duration of the study.~Exclusion Criteria:~* Not have systolic blood pressure (SBP) consistently \< 80 mm Hg, or have clinically significant orthostatic hypotension~* not weigh \> 130 kg~* not have a ventricular assist device (VAD), or anticipate the need for a VAD, during the 28-day study drug treatment period~* not have received placement of an internal cardiac defibrillator (ICD) or external cardiac defibrillator (ECD) within 72 hours before randomization~* not require chronic hemodialysis or peritoneal dialysis to treat renal failure, or had acute dialysis or ultrafiltration within 7 days before randomization~* not have received antibiotic treatment within 7 days before randomization-antibiotics are permissible for any prophylactic use.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): Natrecor (nesiritide)+Standard Care+dobutamine or milrinone 28-day continuous infusion no bolus 3-hour 0.005 mcg/kg/min may be titrated to 0.015 mcg/kg/min
- 002 (Type: PLACEBO_COMPARATOR): Placebo+Standard Care+dobutamine or milrinone 28-day continuous infusion no bolus 3-hour 0.005 mcg/kg/min may be titrated to 0.015 mcg/kg/min

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Inhaled Nitric Oxide Study for Respiratory Failure in Newborns

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Greater than 34 wks gestational age~* One or more of the following diagnoses: primary pulmonary hypertension of the newborn, respiratory distress syndrome, perinatal aspiration syndrome, pneumonia/sepsis, suspected pulmonary hypoplasia~* Oxygenation Index (OI) greater than 15 and less than 25 on 2 arterial blood gases at least 15 min apart~* Indwelling arterial line~* Echocardiography before randomization~* Parental consent~Exclusion Criteria:~* Congenital diaphragmatic hernia~* Known congenital heart disease~* Decision not to provide full therapy

- Gender: ALL
- Minimum Age: None
- Maximum Age: 14 Days
- Healthy Volunteers: f

Study Arms:
- Inhaled Nitric Oxide (Type: EXPERIMENTAL): Inhaled Nitric Oxide (iNO)
- Oxygen (Type: PLACEBO_COMPARATOR): 100% oxygen

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy